Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment

References

• Liang X, Graham DK. Natural killer cell neoplasms. Cancer 2008;112:1425–1436.
   PubMed Web of Science ®Google Scholar
• Chan JKC, Quintanilla-Martinez L, Ferry JA, et al ExtranodalN K/T-cell lymphoma, nasalt type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2008. pp. 285–288.
   Google Scholar
• Ferry JA. Extranodal lymphoma. Arch Pathol Lab Med 2008;132:565–578.
   PubMed Web of Science ®Google Scholar
• Schwartz EJ, Molina-Kirsch H, Zhao S, et al Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: an analysis of 84 cases. Am J Clin Pathol 2008;130:343–351.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Huh J, et al Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res 2007;13:3250–3254.
   PubMed Web of Science ®Google Scholar
• Chiang AK, Wong KY, Liang AC, et al Comparative analysis of Epstein–Barr virus gene polymorphisms in nasal T/NK-cell lymphomas and normal nasal tissues: implications on virus strain selection in malignancy. Int J Cancer 1999;80:356–364.
   PubMed Web of Science ®Google Scholar
• Nagamine M, Takahara M, Kishibe K, et al Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma. Virus Genes 2007;34:47–54.
   PubMed Web of Science ®Google Scholar
• Suzumiya J, Ohshima K, Takeshita M, et al Nasal lymphomas in Japan: a high prevalence of Epstein–Barr virus type A and deletion within the latent membrane protein gene. Leuk Lymphoma 1999;35:567–578.
   PubMed Web of Science ®Google Scholar
• Isobe Y, Sugimoto K, Yang L, et al Epstein–Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res 2004;64:2167–2174.
   PubMed Web of Science ®Google Scholar
• Au WY, Pang A, Choy C, et al Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104:243–249.
   PubMed Web of Science ®Google Scholar
• Wong KF, Zhang YM, Chan JK. Cytogenetic abnormalities in natural killer cell lymphoma/leukaemia – is there a consistent pattern. Leuk Lymphoma 1999;34:241–250.
   PubMed Web of Science ®Google Scholar
• Sakajiri S, Kawamata N, Egashira M, et al Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasms. Jpn J Cancer Res 2001;92:1048–1056.
   PubMedGoogle Scholar
• Siu LL, Chan JK, Wong KF, et al Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol 2003;122:70–77.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Nakamura S, Suzumiya J, et al Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer 2005;104:1022–1031.
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T, et al Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood 2009;113:3931–3937.
   PubMed Web of Science ®Google Scholar
• Oshimi K, Kawa K, Nakamura S, et al NK-cell neoplasms in Japan. Hematology 2005;10:237–245.
   PubMed Web of Science ®Google Scholar
• Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 2007;139:532–544.
   PubMed Web of Science ®Google Scholar
• Kako S, Izutsu K, Ota Y, et al FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007;18:1685–1690.
   PubMed Web of Science ®Google Scholar
• Khong PL, Pang CB, Liang R, et al Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 2008;87:613–621.
   PubMed Web of Science ®Google Scholar
• Lee J, Park YH, Kim WS, et al Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005;41:1402–1408.
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, et al Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54:182–190.
   PubMed Web of Science ®Google Scholar
• Kim TM, Lee SY, Jeon YK, et al Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008;19:1477–1484.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim WS, Park YH, et al Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 2005;92:1226–1230.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612–618.
   PubMed Web of Science ®Google Scholar
• Huang M-J, Jiang Y, Liu W-P, et al Early or up-front radiotherapy Improved survival of localized extranodal NK/T-Cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 2008;70:166–174.
   PubMed Web of Science ®Google Scholar
• You JY, Chi KH, Yang MH, et al Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004;15:618–625.
   PubMed Web of Science ®Google Scholar
• Kim TM, Park YH, Lee SY, et al Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005;106:3785–3790.
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma SY, Au WY, et al Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004;103:216–221.
   PubMed Web of Science ®Google Scholar
• Guo Y, Lu JJ, Ma X, et al Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol 2008;44:23–30.
   PubMed Web of Science ®Google Scholar
• Aviles A, Diaz NR, Neri N, et al Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000;22:215–220.
   PubMedGoogle Scholar
• Li CC, Tien HF, Tang JL, et al Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004;100:366–375.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim KH, Chang MH, et al Whole blood Epstein–Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma 2009:50:757–763.
   PubMed Web of Science ®Google Scholar
• Jung CK, Lee KY, Kim Y, et al Epstein–Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol Int 2001;51:355–363.
   PubMed Web of Science ®Google Scholar
• Lin CW, Chen YH, Chuang YC, et al CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Blood 2003;102:2623–2631.
   PubMed Web of Science ®Google Scholar
• Xiang-Lan M, Zu-Lan S, Dan H, et al Skp2/p27 expression profile is correlated with Epstein–Barr virus status in extranodal nasal-type natural killer cell lymphoma. Transl Res 2008;151:303–308.
   PubMed Web of Science ®Google Scholar
• Kim GE, Lee SW, Chang SK, et al Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 2001;61:261–269.
   PubMed Web of Science ®Google Scholar
• Kim K, Chie EK, Kim CW, et al Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 2005;35:1–5.
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, et al Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181–189.
   PubMed Web of Science ®Google Scholar
• Isobe K, Uno T, Tamaru J, et al Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006;106:609–615.
   PubMed Web of Science ®Google Scholar
• Li YX, Fang H, Liu QF, et al Clinical features and treatment outcome of nasal-type NK/T cell lymphoma of Waldeyer's ring. Blood 2008;112:3057–3064.
   PubMed Web of Science ®Google Scholar
• Wang B, Li XQ, Ma X, et al Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol 2008;83:795–799.
   PubMed Web of Science ®Google Scholar
• Sakata K, Hareyama M, Ohuchi A, et al Treatment of lethal midline granuloma type nasal T-cell lymphoma. Acta Oncol 1997;36:307–311.
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhang Y. Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma. Zhonghua Yi Xue Za Zhi 2001;81:773–775.
   PubMedGoogle Scholar
• Kim BS, Kim TY, Kim CW, et al Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy – result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 2003;42:779–783.
   PubMed Web of Science ®Google Scholar
• Lee KW, Yun T, Kim DW, et al First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/− radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 2006;47:1274–1282.
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes [see comments]. Blood 1992;80:2735–2739.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kenkichi Kita, Hiroshi Miwa, et al Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351–2356.
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhu J, et al Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of l-asparaginase based regimen, and prognostic factors. Hematol Oncol 2006;24:28–32.
   PubMed Web of Science ®Google Scholar
• Kim GE, Yang WI, Lee SW, et al Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leuk Lymphoma 2004;45:1857–1864.
   PubMed Web of Science ®Google Scholar
• Liang R, Todd D, Chan TK, et al Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995;13:666–670.
   PubMed Web of Science ®Google Scholar
• Li YX, Coucke PA, Li JY, et al Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998;83:449–456.
   PubMed Web of Science ®Google Scholar
• Kim GE, Cho JH, Yang WI, et al Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000;18:54–63.
   PubMed Web of Science ®Google Scholar
• Kim WS, Song SY, Ahn YC, et al CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma. Ann Oncol 2001;12:349–352.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Oguchi M, Tobinai K, et al Phase I/II study of concurrent chemoradiotherapy for newly-diagnosed, localized nasal NK/T-cell lymphoma: results of a phase I portion of JCOG0211-DI. Blood (Suppl) 2005;106:2685 (abstract).
   Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: final results of JCOG0211. J Clin Oncol (Meeting Abstracts) 2009;27:8549 (abstract).
   Google Scholar
• Au W, Intragumtornchai T, Nakamura S, et al Clinical and pathological differences between nasal and nasal-type NK/T cell lymphomas: a summary of 136 cases from the International T Cell Lymphoma (ITCL) project. Blood (Suppl) 2006;108:292 (abstract).
   PubMed Web of Science ®Google Scholar
• Kwong YL, Chan AC, Liang R, et al CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997;97:821–829.
   PubMed Web of Science ®Google Scholar
• Pagano L, Gallamini A, Trape G, et al NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey. Ann Oncol 2006;17:794–800.
   PubMed Web of Science ®Google Scholar
• Aviles A, Cleto S, Castaneda C, et al CMED in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology 2007;12:241–244.
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhang Y, et al l-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003;78:163–167.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Coppo P, et al A prospective phase II trial of an l-asparaginase containing regimen in patients with refractory or relapsing extra nodal NK/T-cell lymphoma. Blood (Suppl) 2008;112:579 (abstract).
   Google Scholar
• Yamaguchi M, Suzuki R, Kwong YL, et al Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008;99:1016–1020.
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Fernandez R, et al Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 2003;20:13–17.
   PubMed Web of Science ®Google Scholar
• Ando M, Sugimoto K, Kitoh T, et al Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 2005;130:860–868.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Nomura K, Kanda-Akano Y, et al Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 2003;44:879–882.
   PubMed Web of Science ®Google Scholar
• Nagafuji K, Fujisaki T, Arima F, et al l-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001;74:447–450.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Petit B, Girault S, et al l-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009;20:110–116.
   PubMed Web of Science ®Google Scholar
• Takenaka K, Shinagawa K, Maeda Y, et al High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma 2001;42:1297–1303.
   PubMed Web of Science ®Google Scholar
• Au WY, Lie AK, Liang R, et al Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003;14:1673–1676.
   PubMed Web of Science ®Google Scholar
• Murashige N, Kami M, Kishi Y, et al Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005;130:561–567.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Bang SM, Lee J, et al High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 2006;37:819–824.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Suzumiya J, Nakamura S, et al Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006;37:425–431.
   PubMed Web of Science ®Google Scholar
• Okamura T, Hatsukawa Y, Arai H, et al Blood stem-cell transplantation for chronic active Epstein–Barr virus with lymphoproliferation. Lancet 2000;356:223–224.
   PubMed Web of Science ®Google Scholar
• Teshima T, Miyaji R, Fukuda M, et al Bone-marrow transplantation for Epstein–Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia. Lancet 1996;347:1124.
   PubMed Web of Science ®Google Scholar
• Kawa K, Okamura T, Yasui M, et al Allogeneic hematopoietic stem cell transplantation for Epstein–Barr virus-associated T/NK-cell lymphoproliferative disease. Crit Rev Oncol Hematol 2002;44:251–257.
   PubMed Web of Science ®Google Scholar
• Okamura T, Kishimoto T, Inoue M, et al Unrelated bone marrow transplantation for Epstein–Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant 2003;31:105–111.
   PubMed Web of Science ®Google Scholar
• Sato E, Ohga S, Kuroda H, et al Allogeneic hematopoietic stem cell transplantation for Epstein–Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol 2008;83:721–727.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Matsue K, Takeuchi M, et al Successful treatment of disseminated nasal NK/T-cell lymphoma using double autologous peripheral blood stem cell transplantation. Int J Hematol 2000;71:75–78.
   PubMed Web of Science ®Google Scholar
• Ishitsuka K, Jimi S, Goldmacher VS, et al Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol 2008;141:129–131.
   PubMed Web of Science ®Google Scholar
• Fu L, Gao Z, Zhang X, et al Frequent concomitant epigenetic silencing of the stress-responsive tumor suppressor gene CADM1, and its interacting partner DAL-1 in nasal NK/T-cell lymphoma. Int J Cancer 2009;124:1572–1578.
   PubMed Web of Science ®Google Scholar
• Siu LL, Chan JK, Wong KF, et al Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am J Pathol 2002;160:59–66.
   PubMed Web of Science ®Google Scholar
• Merlo A, Turrini R, Dolcetti R, et al Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opin Biol Ther 2008;8:1265–1294.
   PubMed Web of Science ®Google Scholar
• Cho HI, Hong YS, Lee MA, et al Adoptive transfer of Epstein–Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol 2006;83:66–73.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Gottschalk S, Leen AM, et al Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007;110:2838–2845.
   PubMed Web of Science ®Google Scholar